Eris Lifesciences Delivers Strong Q4: Revenue Soars to ₹7.05 Billion, Net Profit at ₹938 Million
Updated: May 19, 2025 16:42
Image Source: Business Line
Eris Lifesciences Ltd has reported robust financial results for the March 2025 quarter, underscoring its momentum in the branded formulations and specialty pharma space. The company’s consolidated revenue from operations surged to ₹7.05 billion, while net profit reached ₹938.4 million, reflecting sustained growth and operational efficiency.
Key Highlights:
Impressive Revenue Growth: Consolidated operating revenue for Q4 FY25 stood at ₹7.05 billion, marking a significant jump from the previous year’s comparable quarter. This growth was driven by strong performance in domestic branded formulations and the successful integration of recent acquisitions, including Swiss Parenterals.
Profitability Maintained: Net profit for the quarter reached ₹938.4 million, supported by a healthy EBITDA margin of around 27%. The company’s focus on high-margin specialty therapies and cost management contributed to this robust bottom line.
Operational Excellence: Gross profit margins remained strong at over 78%, with disciplined employee and other operational expenses. The company’s EBITDA for the quarter was approximately ₹1.48 billion, up 25% year-on-year, highlighting operational leverage.
Strategic Investments: Eris continued to invest in expanding its product portfolio and market reach, particularly in chronic and sub-chronic therapies. The integration of Swiss Parenterals added ₹550 million in Q4 revenue, further strengthening its presence in parenteral formulations.
Outlook: With a 19% annual revenue growth for FY25 and a 6% rise in full-year net profit, Eris Lifesciences is well-positioned for future expansion, backed by strong cash flows and a focus on specialty segments.
Source: Eris Lifesciences (Investor Presentation, Financials), Moneycontrol, Business Standard